# The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study

> **NCT06652555** · — · NOT_YET_RECRUITING · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 100 (estimated)

## Conditions studied

- ALK
- NSCLC

## Interventions

- **OTHER:** Group 1

## Key facts

- **NCT ID:** NCT06652555
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2026-09-29
- **Final completion:** 2027-09-29
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06652555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06652555, "The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06652555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*